However, specific tumor phenotypic traits are important in determining the prognosis of women with ER+ breast cancer undergoing treatment with selective ER modulators (SERMs) and down-regulators (SERDs) such as tamoxifen and fulvestrant (formerly ICI 182,780), respectively [1,2,3,4,5]. This evidence concerns the gene ESR1 and neoplasm.